anti-CLDN18.2 monoclonal antibody ZL-1211

An engineered monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 monoclonal antibody ZL-1211 specifically targets and binds to CLDN18.2 expressed on tumor cells. The binding induces antibody-dependent cellular cytotoxicity (ADCC) and activates innate and adaptive immunity. This kills and inhibits proliferation of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.